Granza Bio (YC W24)

Granza Bio is a biotech company focused on developing a novel therapeutic delivery platform. Inspired by the body's immune system, they are creating "precision shells" which can package and deliver various cargo types, including attack particles, RNAs, proteins, and genetic modifiers, to specific tissues and organs. This technology addresses limitations of traditional delivery methods, overcoming immunological activation triggered by the delivery vehicle and enabling targeted delivery to hard-to-reach areas.

Granza Bio was founded by cancer and immunology researchers at the University of Oxford in 2024. They have recently secured $7 million in seed funding from investors such as Felicis, Refactor, and Y Combinator, demonstrating strong investor confidence in their platform's potential to revolutionize therapeutic cargo delivery. This funding will support further development of their technology and advance the delivery of cancer treatments and genetic medicines.

Granza Bio is a biotechnology company focused on revolutionizing therapeutic cargo delivery. Inspired by the human immune system, their platform utilizes "precision shells" that can deliver a variety of cargo types, including attack particles, RNAs, proteins, and genetic modifiers, to specific tissues and hard-to-reach organs. Granza Bio's mission is to overcome the limitations of current delivery methods and unlock new possibilities for treating diseases like cancer, autoimmunity, and infections.

Granza Bio promotes a culture of innovation and collaboration, driven by a passion for scientific discovery. The company fosters a supportive and inclusive environment where employees are encouraged to contribute their unique perspectives and expertise. Their commitment to advancing therapeutic delivery with precision shells reflects a dedication to solving complex challenges in the field of medicine and creating a positive impact on patients' lives.